IP Library Granted Patent US 12,404,549
Granted Patent B2
US 12,404,549 · App. 17/568,077 · Granted Sep 2, 2025

Methods and compositions for stabilizing nucleic acid-nucleotide-polymerase complexes

Inventors: Morassa Mohseni Middleton (San Diego, CA); Mark C. Wallen (San Diego, CA); Pinar Iyidogan (San Diego, CA); Michael James Schmidt (San Diego, CA); Brittany A. Rohrman (La Jolla, CA); Ying Lin Liu (San Diego, CA); Fabian Block (San Diego, CA); Arnold Oliphant (Morgan Hill, CA)
Assignee: Pacific Biosciences of California, Inc.
C12Q1/6869C12Q1/6816C12Q1/6832
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,404,549
App. No.
17/568,077
Granted
Sep 2, 2025
Kind
B2
Abstract

Methods, compositions, kits and apparatuses that include a fluid, the fluid containing a ternary complex and Li + , wherein the ternary complex includes a primed template nucleic acid, a polymerase, and a nucleotide cognate for the next correct base for the primed template nucleic acid molecule. As an alternative or addition to Li + , the fluid can contain betaine or a metal ion that inhibits polymerase catalysis such as Ca 2+ . In addition to Li + , the fluid can contain polyethylenimine (PEI) with or without betaine.

Claims (26)

1. A composition, comprising a fluid, the fluid comprising a ternary complex and Li + , wherein the ternary complex comprises a primed template nucleic acid molecule comprising reversible terminator moiety, a polymerase, and a nucleotide cognate for the next correct base for the primed template nucleic acid molecule.

2. A kit, comprising:

labeled nucleotides;

unlabeled reversibly terminated nucleotides; and

a stabilizing fluid comprising Li + .

3. The kit of claim 2 , wherein the stabilizing fluid further comprises betaine.

4. The kit of claim 2 , wherein the stabilizing fluid further comprises polyethylenimine (PEI).

5. The kit of claim 2 , wherein the stabilizing fluid further comprises betaine and polyethylenimine (PEI).

6. The kit of claim 2 , wherein the stabilizing fluid further comprises an inhibitory metal ion.

7. The kit of claim 6 , wherein the inhibitory metal ion is Ca 2+ .

8. The kit of claim 2 , further comprising a deblocking reagent.

9. The kit of claim 2 , further comprising a polymerase.

10. The kit of claim 9 , wherein the polymerase is unlabeled.

11. The kit of claim 9 , wherein the polymerase is an exo minus Klenow fragment.

12. The kit of claim 2 , wherein the unlabeled reversibly terminated nucleotides are in an extension reaction mixture.

13. The kit of claim 2 , wherein the labeled nucleotides are in a reaction mixture for ternary complex formation.

14. The kit of claim 2 , wherein the labeled nucleotides comprise labels that are detectible by fluorescence emission.

15. The kit of claim 2 , wherein the labeled nucleotides comprise nucleotides of each of 4 different bases.

16. The kit of claim 2 , further comprising a cartridge having reservoirs to contain the labeled nucleotides, unlabeled reversibly terminated nucleotides, and the stabilizing fluid.

17. The kit of claim 16 , wherein the cartridge further comprises fluidic components for transferring reagents from the reservoirs to a detection instrument.

18. A system comprising:

a flow cell;

reagents comprising labeled nucleotides, unlabeled reversibly terminated nucleotides, and a stabilizing fluid comprising Li + ;

a fluidic system configured to deliver the reagents to the flow cell; and

a detection apparatus configured to detect the flow cell.

19. The system of claim 18 , wherein the fluidic system comprises a cartridge having reservoirs to contain the labeled nucleotides, unlabeled reversibly terminated nucleotides, and the stabilizing fluid.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 1, 2022
From: OMNIOME, LLC
To: PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
Reel/Frame 059278/0153 →
MERGER Recorded Feb 2, 2022
From: OMNIOME, INC.
To: OMNIOME, LLC
Reel/Frame 058952/0352 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 26, 2022
From: MIDDLETON, MORASSA MOHSENI; WALLEN, MARK C.; IYIDOGAN, PINAR; SCHMIDT, MICHAEL JAMES; ROHRMAN, BRITTANY A.; LIU, YING LIN; BLOCK, FABIAN; OLIPHANT, ARNOLD
To: OMNIOME, INC.
Reel/Frame 058783/0359 →
Continuity (4)
Continuation 16516808 · Jul 19, 2019
Continuation 16355361 · Mar 15, 2019
Provisional Application 62662888 · Apr 26, 2018
Related Publication 20220290216A1 · Sep 15, 2022
References Cited (52)
US 7057026B2 · Barnes et al. · 2006 [cited by applicant]
US 7211414B2 · Hardin et al. · 2007 [cited by applicant]
US 7315019B2 · Turner et al. · 2008 [cited by applicant]
US 7329492B2 · Hardin et al. · 2008 [cited by applicant]
US 7405281B2 · Xu et al. · 2008 [cited by applicant]
US 7482120B2 · Buzby · 2009 [cited by applicant]
US 7544794B1 · Benner · 2009 [cited by applicant]
US 7956171B2 · Siddiqi · 2011 [cited by applicant]
US 8034923B1 · Benner et al. · 2011 [cited by applicant]
US 8071755B2 · Efcavitch et al. · 2011 [cited by applicant]
US 8808989B1 · Efcavitch et al. · 2014 [cited by applicant]
US 9399798B2 · Stupi et al. · 2016 [cited by applicant]
US 9650671B2 · Fedorov et al. · 2017 [cited by applicant]
US 9932631B1 · Dambacher et al. · 2018 [cited by applicant]
US 9951385B1 · Vijayan et al. · 2018 [cited by applicant]
US 10077470B2 · Vijayan et al. · 2018 [cited by applicant]
US 10161003B2 · Stromberg et al. · 2018 [cited by applicant]
US 10400272B1 · Middleton et al. · 2019 [cited by applicant]
US 20080108082A1 · Rank et al. · 2008 [cited by applicant]
US 20140057339A1 · Esfandyarpour et al. · 2014 [cited by applicant]
US 20150184238A1 · Eshoo · 2015 [cited by examiner]
US 20150203908A1 · Fedorov et al. · 2015 [cited by applicant]
US 20150284788A1 · Fang et al. · 2015 [cited by applicant]
US 20170022553A1 · Vijayan et al. · 2017 [cited by applicant]
US 20170022555A1 · Olejnik · 2017 [cited by examiner]
US 20170132361A1 · Liang et al. · 2017 [cited by applicant]
US 20170314064A1 · Iyidogan et al. · 2017 [cited by applicant]
US 20180044727A1 · Vijayan et al. · 2018 [cited by applicant]
US 20180187245A1 · Dambacher et al. · 2018 [cited by applicant]
US 20180208983A1 · Dambacher et al. · 2018 [cited by applicant]
US 20190048404A1 · Dambacher · 2019 [cited by applicant]
WO 9106678A1 · 1991 [cited by applicant]
WO 2004018497A2 · 2004 [cited by applicant]
WO 2007123744A2 · 2007 [cited by applicant]
WO 2015045606A1 · 2015 [cited by applicant]
WO 2017184996A1 · 2017 [cited by applicant]
EP23170384.4, “Extended European Search Report”, Oct. 26, 2023, 9 pages. [cited by applicant]
CN201980027733.5, “Office Action” with machine translation, Mar. 6, 2024, 13 pages. [cited by applicant]
U.S. Appl. No. 16/355,361, “Notice of Allowance”, Jul. 9, 2019, 10 pages. [cited by applicant]
U.S. Appl. No. 16/516,808, “Final Office Action”, Jun. 24, 2021, 7 pages. [cited by applicant]
U.S. Appl. No. 16/516,808, “Non-Final Office Action”, Jan. 7, 2021, 10 pages. [cited by applicant]
U.S. Appl. No. 16/516,808, “Notice of Allowance”, Oct. 6, 2021, 7 pages. [cited by applicant]
Bentley et al., “Accurate Whole Human Genome Sequencing Using Reversible Terminator Chemistry”, Nature, vol. 456, No. 7218, Nov. 6, 2008, pp. 53-59. [cited by applicant]
PCT/US2019/022540, “International Preliminary Report on Patentability”, Nov. 5, 2020, 8 pages. [cited by applicant]
PCT/US2019/022540, “International Search Report and Written Opinion”, May 3, 2019, 11 pages. [cited by applicant]
JP2023-102320, “Office Action”, Dec. 12, 2023, 7 pages. [cited by applicant]
CN201980027733.5, “Office Action”, Sep. 28, 2024, 9 pages. [cited by applicant]
AU2019261218, “First Examination Report”, Oct. 24, 2024, 4 pages. [cited by applicant]
JP2020-559389, “Office Action”, Aug. 1, 2023, 4 pages. [cited by applicant]
JP2023-102320, “Office Action”, Aug. 1, 2023, 9 pages. [cited by applicant]
JP2020-559389, “Office Action” with Machine Translation, Mar. 19, 2024, 6 pages. [cited by applicant]
JP2020-559389, “Office Action”, Jan. 24, 2023, 9 pages. [cited by applicant]